Fabry disease: a rare disorder calling for personalized medicine
Authors:
Open Access
- 13 April 2024
- journal article
- review article
- Published by Springer Nature in International Urology and Nephrology
- Vol. 56 (10) , 3161-3172
Abstract
Fabry Disease (FD) is a genetic disease caused by a deficiency in the activity of lysosomal galactosidase A (α-GalA), an enzyme responsible for the catabolism of globotriaosylceramide (Gb3). Since lysosomes are present throughout the body and play a crucial role in catabolism and recycling of cytosolic compounds, FD can affect multiple organs and result in various symptoms, including renal, cardiovascular, neurological, cutaneous, and ophthalmic manifestations. Due to the nonspecific symptoms and the rarity of FD, it is often diagnosed late in life. However, introducing targeted therapies such as enzyme replacement therapy (ERT) and chaperone therapy has significantly improved FD's natural history and prognosis by restoring α-GalA enzyme activity. Despite the advancements, there are limitations to the currently available therapies, which has prompted research into new potential treatments for FD, including alternative forms of enzyme replacement therapy, substrate reduction therapy, mRNA therapy, and genetic therapy. In this review, we analyze the epidemiology, pathophysiology, and treatment of FD, with particular emphasis on promising therapeutic opportunities that could shift the treatment of this rare disease from a standardized to a personalized approach soon.Keywords
Funding Information
- Alma Mater Studiorum - Università di Bologna
This publication has 85 references indexed in Scilit:
- Pathology and pathogenic pathways in fabry nephropathyClinical and Experimental Nephrology, 2021
- Assessment of small fiber neuropathy in patients carrying the non‐classical Fabry variant p.D313YMuscle & Nerve, 2021
- Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human PrimatesThe American Journal of Human Genetics, 2019
- Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trialJournal of Inherited Metabolic Disease, 2019
- Pharmacokinetics, pharmacodynamics, and safety of moss‐aGalactosidase A in patients with Fabry diseaseJournal of Inherited Metabolic Disease, 2019
- Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectivesAdvanced Drug Delivery Reviews, 2017
- Mannose receptor‐mediated delivery of moss‐made α‐galactosidase A efficiently corrects enzyme deficiency in Fabry miceJournal of Inherited Metabolic Disease, 2015
- Gastrointestinal Symptoms in 342 Patients With Fabry Disease: Prevalence and Response to Enzyme Replacement TherapyClinical Gastroenterology and Hepatology, 2007
- Physiological characterization of neuropathy in Fabry's diseaseMuscle & Nerve, 2002
- The Neuropathology of Hereditary Dystopic LipidosisArchives of Neurology, 1963